Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab to prevent early cardiac allograft vasculopathy
NCT04193306Phase 4Unknown
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Nov 2019
- Primary completion
- May 2025
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alirocumab in cardiac allograft vasculopathy (CAV) and hypercholesterolemia, sponsored by Institute for Clinical and Experimental Medicine. Primary endpoint: calculated LDL cholesterol concentration at 12 months. Status: unknown.
02
Drugs
alirocumab
03
Conditions
cardiac allograft vasculopathy (CAV)hypercholesterolemia
Beyond the preview
Go deeper on NCT04193306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04193306.